Progenics Pharmaceuticals, Inc. (PGNX) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q2 EPS of ($0.17), $0.03 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.83 million.
For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- SS&C Technologies shares fall on weak Q4 revenue outlook
- Truist names top clean energy stocks to watch ahead of Q3 earnings season
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
